Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886746 | 0.92 | ALDH1A1 (0.44) | MAPTLMNARAB9ATP53SMN1; SMN2 | |
| SCHEMBL5887335 | 0.87 | L3MBTL1 (0.39) | LMNATP53SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5886876 | 0.87 | RAB9A (0.45) | MAPTLMNARAB9ATP53NPC1 | |
| SCHEMBL5886972 | 0.86 | MEN1 (0.37) | MAPTLMNARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5887294 | 0.86 | MAPK8 (0.40) | MAPTLMNARAB9ATP53NPC1 | |
| SCHEMBL5886906 | 0.85 | MMP13 (0.40) | MAPTLMNARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5887213 | 0.84 | HPGD (0.45) | MAPTLMNATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL5886808 | 0.83 | KDM4E (0.45) | MAPTLMNARAB9ATP53NPC1 | |
| SCHEMBL5886860 | 0.83 | USP25 (0.46) | MAPTLMNARAB9ATP53NPC1 | |
| SCHEMBL5887620 | 0.83 | HPGD (0.54) | MAPTLMNARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | MAPT 1614/4885LMNA 711/4885RAB9A 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.